No Data
No Data
Clearside Biomedical Announces Publication of Critical Insights Into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Clearside Biomedical Highlights Advancements in Drug Delivery
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now
Clearside Biomedical Is Maintained at Buy by Chardan Capital
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position
Unlock the Full List